Merck (MRK +3.3%) says that the Data Safety Monitoring Board will allow the company to continue...

|About: Merck & Co Inc. (MRK)|By:, SA News Editor

Merck (MRK +3.3%) says that the Data Safety Monitoring Board will allow the company to continue with its large-scale trial of its blockbuster Vytorin cholesterol drug, indicating that no safety issues have come up. Some analysts had hoped that the trial would already have demonstrated Vytorin's effectiveness and so could be halted. Alas, the study will continue until September 2014. (PR)